BREAKING: Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)
Opexa Therapeutics, Inc. today announced the initiation of a Phase IIb clinical trial of Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), in patients with Secondary Progressive Multiple Sclerosis (SPMS). The therapy is specifically tailored to each patient’s individual disease profile and has demonstrated superior safety and encouraging indications of efficacy in previous clinical studies in MS that included the treatment of SPMS patients.
Read more »A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Read more »Ampyra Walks Away with FDA Approval
The U.S. Food and Drug Administration (FDA) has approved the first drug designed to improve walking in adults with multiple sclerosis.
Read more »Avanir Shares Rise on Zenvia Trial Data
Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis drug Zenvia met its goal in a six-month clinical trial.
Read more »Opexa Shares Soar on Multiple Sclerosis Trial Data
Opexa Therapeutics announced that 83 percent of clinical trial patients taking its therapeutic vaccine Tovaxin remained relapse-free for a year.
Read more »MediciNova to Buy Avigen for $37 Million
Pharmaceutical company MediciNova announced that it will buy Avigen (AVGN) for $1.24 per share, approximately $37 million.
Read more »Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness”
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Read more »